TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy

DRUG2 trials

Sponsors

Shanghai Junshi Bioscience Co., Ltd., Guangdong Association of Clinical Trials

Conditions

Non-Small Cell Lung CancerTreatment-naive Advanced Non-small Cell Lung Cancer

Phase 3

A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC

CompletedNCT03856411

Shanghai Junshi Bioscience Co., Ltd.Treatment-naive Advanced Non-small Cell Lung Cancer

Start: 2019-03-18End: 2023-01-09Updated: 2023-02-01

Unknown Phase

Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC

Not yet recruitingNCT06709274

Guangdong Association of Clinical TrialsNon-Small Cell Lung Cancer

Start: 2024-11-30End: 2032-01-31Target: 342Updated: 2024-11-29

Related Papers

Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial

Signal Transduction and Targeted Therapy2024-12-249 citations

Decision model for durable clinical benefit from front- or late-line immunotherapy alone or with chemotherapy in non-small cell lung cancer.

2024-05-226 citations

468 Characteristics of toripalimab: a next generation anti-PD-1 antibody with potent T cell activation and enhanced clinical efficacy irrespective of PD-L-1 status

Regular and Young Investigator Award Abstracts2023-10-311 citations

Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations.

Journal of Clinical Oncology2023-06-016 citations

Cost-effectiveness analysis of toripalimab plus chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer in China.

2023-05-296 citations

Final progression-free survival, interim overall survival, and biomarker analyses of CHOICE-01: A phase 3 study of toripalimab versus placebo in combination with first-line chemotherapy for advanced NSCLC without EGFR/ALK mutations.

Journal of Clinical Oncology2022-06-018 citations

Final progression-free survival, interim overall survival, and biomarker analyses of CHOICE-01: A phase III study of toripalimab versus placebo in combination with first-line chemotherapy for advanced NSCLC without EGFR/ALK mutations

Journal of Clinical Oncology2022-03-175 citations